Past decline versus current EGFR and subsequent mortality risk

David M.J. Naimark, Morgan E. Grams, Kunihiro Matsushita, Corri Black, Iefke Drion, Caroline S. Fox, Lesley A. Inker, Areef Ishani, Sun Ha Jee, Akihiko Kitamura, Janice P. Lea, Joseph Nally, Carmen Alicia Peralta, Dietrich Rothenbacher, Seungho Ryu, Marcello Tonelli, Hiroshi Yatsuya, Josef Coresh, Ron T. Gansevoort, David G. WarnockMark Woodward, Paul E. De Jong

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

A single determination of EGFR associates with subsequent mortality risk. Prior decline in EGFR indicates loss of kidney function, but the relationship tomortality risk is uncertain. We conducted an individual-level meta-analysis of the risk ofmortality associatedwith antecedent EGFR slope, adjusting for established risk factors, including last EGFR, among 1.2million subjects from 12 CKD and 22 other cohorts within the CKD Prognosis Consortium. Over a 3-year antecedent period, 12% of participants in the CKD cohorts and 11% in the other cohorts had an EGFR slope,25ml/min per 1.73 m2 per year, whereas 7%and 4% had a slope .5 ml/min per 1.73 m2 per year, respectively. Compared with a slope of 0 ml/min per 1.73 m2 per year, a slope of 26 ml/min per 1.73 m2 per year associated with adjusted hazard ratios for all-cause mortality of 1.25 (95% confidence interval [95% CI], 1.09 to 1.44) among CKD cohorts and 1.15 (95% CI, 1.01 to 1.31) among other cohorts during a follow-up of 3.2 years. A slope of +6 ml/min per 1.73 m2 per year also associated with higher all-cause mortality risk, with adjusted hazard ratios of 1.58 (95% CI, 1.29 to 1.95) among CKD cohorts and 1.43 (95% CI, 1.11 to 1.84) among other cohorts. Results were similar for cardiovascular and noncardiovascular causes of death and stronger for longer antecedent periods (3 versus ,3 years). We conclude that prior decline or rise in EGFR associates with an increased risk of mortality, independent of current EGFR.

Original languageEnglish
Pages (from-to)2456-2466
Number of pages11
JournalJournal of the American Society of Nephrology
Volume27
Issue number8
DOIs
Publication statusPublished - 01-01-2016

Fingerprint

Mortality
Confidence Intervals
Meta-Analysis
Cause of Death
Kidney

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Naimark, D. M. J., Grams, M. E., Matsushita, K., Black, C., Drion, I., Fox, C. S., ... De Jong, P. E. (2016). Past decline versus current EGFR and subsequent mortality risk. Journal of the American Society of Nephrology, 27(8), 2456-2466. https://doi.org/10.1681/ASN.2015060688
Naimark, David M.J. ; Grams, Morgan E. ; Matsushita, Kunihiro ; Black, Corri ; Drion, Iefke ; Fox, Caroline S. ; Inker, Lesley A. ; Ishani, Areef ; Jee, Sun Ha ; Kitamura, Akihiko ; Lea, Janice P. ; Nally, Joseph ; Peralta, Carmen Alicia ; Rothenbacher, Dietrich ; Ryu, Seungho ; Tonelli, Marcello ; Yatsuya, Hiroshi ; Coresh, Josef ; Gansevoort, Ron T. ; Warnock, David G. ; Woodward, Mark ; De Jong, Paul E. / Past decline versus current EGFR and subsequent mortality risk. In: Journal of the American Society of Nephrology. 2016 ; Vol. 27, No. 8. pp. 2456-2466.
@article{c11a6e4796024cac9a53ec44de2519ee,
title = "Past decline versus current EGFR and subsequent mortality risk",
abstract = "A single determination of EGFR associates with subsequent mortality risk. Prior decline in EGFR indicates loss of kidney function, but the relationship tomortality risk is uncertain. We conducted an individual-level meta-analysis of the risk ofmortality associatedwith antecedent EGFR slope, adjusting for established risk factors, including last EGFR, among 1.2million subjects from 12 CKD and 22 other cohorts within the CKD Prognosis Consortium. Over a 3-year antecedent period, 12{\%} of participants in the CKD cohorts and 11{\%} in the other cohorts had an EGFR slope,25ml/min per 1.73 m2 per year, whereas 7{\%}and 4{\%} had a slope .5 ml/min per 1.73 m2 per year, respectively. Compared with a slope of 0 ml/min per 1.73 m2 per year, a slope of 26 ml/min per 1.73 m2 per year associated with adjusted hazard ratios for all-cause mortality of 1.25 (95{\%} confidence interval [95{\%} CI], 1.09 to 1.44) among CKD cohorts and 1.15 (95{\%} CI, 1.01 to 1.31) among other cohorts during a follow-up of 3.2 years. A slope of +6 ml/min per 1.73 m2 per year also associated with higher all-cause mortality risk, with adjusted hazard ratios of 1.58 (95{\%} CI, 1.29 to 1.95) among CKD cohorts and 1.43 (95{\%} CI, 1.11 to 1.84) among other cohorts. Results were similar for cardiovascular and noncardiovascular causes of death and stronger for longer antecedent periods (3 versus ,3 years). We conclude that prior decline or rise in EGFR associates with an increased risk of mortality, independent of current EGFR.",
author = "Naimark, {David M.J.} and Grams, {Morgan E.} and Kunihiro Matsushita and Corri Black and Iefke Drion and Fox, {Caroline S.} and Inker, {Lesley A.} and Areef Ishani and Jee, {Sun Ha} and Akihiko Kitamura and Lea, {Janice P.} and Joseph Nally and Peralta, {Carmen Alicia} and Dietrich Rothenbacher and Seungho Ryu and Marcello Tonelli and Hiroshi Yatsuya and Josef Coresh and Gansevoort, {Ron T.} and Warnock, {David G.} and Mark Woodward and {De Jong}, {Paul E.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1681/ASN.2015060688",
language = "English",
volume = "27",
pages = "2456--2466",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "8",

}

Naimark, DMJ, Grams, ME, Matsushita, K, Black, C, Drion, I, Fox, CS, Inker, LA, Ishani, A, Jee, SH, Kitamura, A, Lea, JP, Nally, J, Peralta, CA, Rothenbacher, D, Ryu, S, Tonelli, M, Yatsuya, H, Coresh, J, Gansevoort, RT, Warnock, DG, Woodward, M & De Jong, PE 2016, 'Past decline versus current EGFR and subsequent mortality risk', Journal of the American Society of Nephrology, vol. 27, no. 8, pp. 2456-2466. https://doi.org/10.1681/ASN.2015060688

Past decline versus current EGFR and subsequent mortality risk. / Naimark, David M.J.; Grams, Morgan E.; Matsushita, Kunihiro; Black, Corri; Drion, Iefke; Fox, Caroline S.; Inker, Lesley A.; Ishani, Areef; Jee, Sun Ha; Kitamura, Akihiko; Lea, Janice P.; Nally, Joseph; Peralta, Carmen Alicia; Rothenbacher, Dietrich; Ryu, Seungho; Tonelli, Marcello; Yatsuya, Hiroshi; Coresh, Josef; Gansevoort, Ron T.; Warnock, David G.; Woodward, Mark; De Jong, Paul E.

In: Journal of the American Society of Nephrology, Vol. 27, No. 8, 01.01.2016, p. 2456-2466.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Past decline versus current EGFR and subsequent mortality risk

AU - Naimark, David M.J.

AU - Grams, Morgan E.

AU - Matsushita, Kunihiro

AU - Black, Corri

AU - Drion, Iefke

AU - Fox, Caroline S.

AU - Inker, Lesley A.

AU - Ishani, Areef

AU - Jee, Sun Ha

AU - Kitamura, Akihiko

AU - Lea, Janice P.

AU - Nally, Joseph

AU - Peralta, Carmen Alicia

AU - Rothenbacher, Dietrich

AU - Ryu, Seungho

AU - Tonelli, Marcello

AU - Yatsuya, Hiroshi

AU - Coresh, Josef

AU - Gansevoort, Ron T.

AU - Warnock, David G.

AU - Woodward, Mark

AU - De Jong, Paul E.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - A single determination of EGFR associates with subsequent mortality risk. Prior decline in EGFR indicates loss of kidney function, but the relationship tomortality risk is uncertain. We conducted an individual-level meta-analysis of the risk ofmortality associatedwith antecedent EGFR slope, adjusting for established risk factors, including last EGFR, among 1.2million subjects from 12 CKD and 22 other cohorts within the CKD Prognosis Consortium. Over a 3-year antecedent period, 12% of participants in the CKD cohorts and 11% in the other cohorts had an EGFR slope,25ml/min per 1.73 m2 per year, whereas 7%and 4% had a slope .5 ml/min per 1.73 m2 per year, respectively. Compared with a slope of 0 ml/min per 1.73 m2 per year, a slope of 26 ml/min per 1.73 m2 per year associated with adjusted hazard ratios for all-cause mortality of 1.25 (95% confidence interval [95% CI], 1.09 to 1.44) among CKD cohorts and 1.15 (95% CI, 1.01 to 1.31) among other cohorts during a follow-up of 3.2 years. A slope of +6 ml/min per 1.73 m2 per year also associated with higher all-cause mortality risk, with adjusted hazard ratios of 1.58 (95% CI, 1.29 to 1.95) among CKD cohorts and 1.43 (95% CI, 1.11 to 1.84) among other cohorts. Results were similar for cardiovascular and noncardiovascular causes of death and stronger for longer antecedent periods (3 versus ,3 years). We conclude that prior decline or rise in EGFR associates with an increased risk of mortality, independent of current EGFR.

AB - A single determination of EGFR associates with subsequent mortality risk. Prior decline in EGFR indicates loss of kidney function, but the relationship tomortality risk is uncertain. We conducted an individual-level meta-analysis of the risk ofmortality associatedwith antecedent EGFR slope, adjusting for established risk factors, including last EGFR, among 1.2million subjects from 12 CKD and 22 other cohorts within the CKD Prognosis Consortium. Over a 3-year antecedent period, 12% of participants in the CKD cohorts and 11% in the other cohorts had an EGFR slope,25ml/min per 1.73 m2 per year, whereas 7%and 4% had a slope .5 ml/min per 1.73 m2 per year, respectively. Compared with a slope of 0 ml/min per 1.73 m2 per year, a slope of 26 ml/min per 1.73 m2 per year associated with adjusted hazard ratios for all-cause mortality of 1.25 (95% confidence interval [95% CI], 1.09 to 1.44) among CKD cohorts and 1.15 (95% CI, 1.01 to 1.31) among other cohorts during a follow-up of 3.2 years. A slope of +6 ml/min per 1.73 m2 per year also associated with higher all-cause mortality risk, with adjusted hazard ratios of 1.58 (95% CI, 1.29 to 1.95) among CKD cohorts and 1.43 (95% CI, 1.11 to 1.84) among other cohorts. Results were similar for cardiovascular and noncardiovascular causes of death and stronger for longer antecedent periods (3 versus ,3 years). We conclude that prior decline or rise in EGFR associates with an increased risk of mortality, independent of current EGFR.

UR - http://www.scopus.com/inward/record.url?scp=85016432507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016432507&partnerID=8YFLogxK

U2 - 10.1681/ASN.2015060688

DO - 10.1681/ASN.2015060688

M3 - Article

C2 - 26657865

AN - SCOPUS:85016432507

VL - 27

SP - 2456

EP - 2466

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 8

ER -

Naimark DMJ, Grams ME, Matsushita K, Black C, Drion I, Fox CS et al. Past decline versus current EGFR and subsequent mortality risk. Journal of the American Society of Nephrology. 2016 Jan 1;27(8):2456-2466. https://doi.org/10.1681/ASN.2015060688